CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CareDx, Inc's (CDNA) CEO Peter Maag On Q3 2020 Results - Quick Version Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that effective November 1, 2020, Peter Maag, current Chairman and Chief Executive Officer, will assume the role of Executive Chairman of the Board of Directors, and Reginald Seeto, currently President and Chief Business Officer, will assume the role of President and Chief Executive Officer and will join the CareDx Board of Directors.

Peter Maag Appointed Executive Chairman of the Board of Directors of CareDx; Reginald Seeto Appointed President and CEO

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the quarter ended September 30, 2020.

CareDx Reports Third Quarter 2020 Results

CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CareDx (CDNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

General nephrologists show a growing interest in AlloSure with 11 abstracts and educational symposiums at the largest nephrology meeting General nephrologists show a growing interest in AlloSure with 11 abstracts and educational symposiums at the largest nephrology meeting

CareDx Showcases Leading Transplant Data at ASN 2020

CMS believes AlloMap reimbursement process is clinically appropriate for heart transplant patients CMS believes AlloMap reimbursement process is clinically appropriate for heart transplant patients

Medicare Proposes to Maintain Current Reimbursement Process for AlloMap

Virtual events to highlight newest innovation and solutions for HLA labs during ASHI conference Virtual events to highlight newest innovation and solutions for HLA labs during ASHI conference

CareDx Leads in Innovation with AlloSeq Portfolio at ASHI 2020

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it will release financial results for the third quarter 2020 after the close of trading on Thursday, October 29, 2020. Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.

CareDx to Report Third Quarter 2020 Financial Results

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why CareDx (CDNA) is a Great Momentum Stock to Buy

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced preliminary unaudited revenue for the three months ended September 30, 2020.

CareDx Reports Preliminary Third Quarter 2020 Revenue

LARGO and The University of Texas Health Science Center at San Antonio publications demonstrate benefits of AlloSure in lung transplant patients LARGO and The University of Texas Health Science Center at San Antonio publications demonstrate benefits of AlloSure in lung transplant patients

CareDx Announces Publication of Pivotal AlloSure Lung Data

Final decision on AlloSure Heart paves the way for HeartCare, the most comprehensive multi-modality tool available to heart transplant patients Final decision on AlloSure Heart paves the way for HeartCare, the most comprehensive multi-modality tool available to heart transplant patients

CareDx Receives Final Medicare Coverage Decision for AlloSure Heart

AlloCare mobile app is now available to help transplant patients manage their health, communicate efficiently, and stay connected AlloCare mobile app is now available to help transplant patients manage their health, communicate efficiently, and stay connected

CareDx Launches AlloCare at Virtual Transplant Festival

AlloSure and AlloSeq cfDNA surveillance tools to be featured along with four virtual symposia at international congress AlloSure and AlloSeq cfDNA surveillance tools to be featured along with four virtual symposia at international congress

CareDx Shares Latest Clinical Data at the TTS 2020 Virtual Conference

CareDx appoints key hires in digital services, laboratory operations, business development and market access CareDx appoints key hires in digital services, laboratory operations, business development and market access

CareDx Strengthens Leadership Team to Accelerate Growth

SOUTH SAN FRANCISCO, Calif., Sept.  02, 2020  (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today that the company plans to participate in two upcoming conferences.

CareDx to Participate at Upcoming Conferences

CareDx, Inc (CDNA) CEO Peter Maag on Q2 2020 Results - Earnings Call Transcript

CareDx (CDNA) delivered earnings and revenue surprises of 166.67% and 17.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Q2 Earnings and Revenues Surpass Estimates

Patient-focused during COVID-19 pandemic and succeeding Patient-focused during COVID-19 pandemic and succeeding

CareDx Reports Second Quarter 2020 Results

SOUTH SAN FRANCISCO, Calif., July  30, 2020  (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11-13, 2020. CareDx’s management is scheduled to present on Wednesday, August 12, 2020, at 1:00 p.m. EDT. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at  investors.caredxinc.com .

CareDx to Participate at the Canaccord Genuity 40th Annual Growth Conference

Anthem

Cigna

Molina Healthcare

Teladoc

Companies across the healthcare sector experience a mixed impact from coronavirus. While some gain traction from a surge in virtual care, the rest suffers demand woes and supply-chain glitches.

5 Healthcare Stocks to Beat on Q2 Earnings Despite Coronavirus

SOUTH SAN FRANCISCO, Calif., July  16, 2020  (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it will release financial results for the second quarter 2020 after the close of trading on Tuesday, August 4, 2020. Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.

CareDx to Report Second Quarter 2020 Financial Results

Peter Maag is Presenting on AI in Transplant Care at the AAKP and George Washington International Patient Summit Peter Maag is Presenting on AI in Transplant Care at the AAKP and George Washington International Patient Summit

CareDx Chairman and CEO Peter Maag to Present at Global Kidney Innovations Summit

Quest Diagnostics

Exact Sciences

It is very possible by now that many adults have had a telehealth conference or checkup.

Telehealth Is Here to Stay: 4 Stocks to Buy Now With Huge Potential

Head to head data shows that not all dd-cfDNA is the same Head to head data shows that not all dd-cfDNA is the same

News for CareDx Stock (CDNA)